Strategic partnership Asuragen has formed a collaboration with Oxford Nanopore Technologies to co-develop and market the AmplideX Nanopore Carrier Plus Kit, signaling a move toward integrated sequencing and PCR-based workflows that may open upsell opportunities for comprehensive genetic screening solutions.

Carrier screening expansion Recent news highlights a focus on carrier screening research and panel development, indicating demand for expanded, high-throughput tests that combine long-read sequencing with existing PCR capabilities.

Integrated tech stack With activities spanning PCR, long-read sequencing, and software for analysis, there is potential to cross-sell complementary reagents, assay kits, and computational tools to streamline end-to-end diagnostic workflows.

Clinical validation activity Participation in AMP conferences and publishing novel clinical testing data suggests opportunities to position partnering products to labs pursuing regulatory-grade validation and publication-ready pipelines.

Growth potential Revenue in the mid-range tens of millions and a strategic branding alignment under Bio-Techne Diagnostics points to potential for expanded market reach, including adjacent academic and clinical customers seeking integrated diagnostic solutions.